Micromet Obtains FDA Feedback on Registration Strategy for Blinatumomab in Relapsed/Refractory ALL

Micromet, Inc. (NASDAQ:

) today outlined a clinical development plan intended to support U.S. registration of its lead product candidate blinatumomab in patients with B-precursor relapsed/refractory acute lymphoblastic leukemia. The plan incorporates advice received from the U.S. Food and Drug Administration within the context of a Type C meeting.